Absci Co. (NASDAQ:ABSI) Receives Consensus Rating of “Buy” from Analysts

Absci Co. (NASDAQ:ABSI) has been assigned an average recommendation of “Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have covered the stock in the last year is $8.57.

Several equities research analysts have recently commented on the company. Guggenheim restated a “buy” rating and set a $10.00 price objective on shares of Absci in a report on Tuesday, December 3rd. Needham & Company LLC assumed coverage on Absci in a report on Wednesday, January 22nd. They set a “buy” rating and a $9.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Absci in a report on Friday, January 17th. Finally, KeyCorp decreased their price objective on Absci from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th.

Absci Price Performance

Shares of ABSI opened at $3.85 on Friday. The firm has a market cap of $442.20 million, a PE ratio of -4.14 and a beta of 2.11. Absci has a 52-week low of $2.45 and a 52-week high of $6.72. The business’s 50 day moving average price is $3.82 and its two-hundred day moving average price is $3.78. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63.

Institutional Investors Weigh In On Absci

Institutional investors have recently bought and sold shares of the stock. PCA Investment Advisory Services Inc. bought a new stake in Absci during the fourth quarter worth $26,000. Alpha Cubed Investments LLC bought a new position in Absci in the 4th quarter valued at $26,000. Ballentine Partners LLC bought a new position in Absci in the 4th quarter valued at $27,000. BNP Paribas Financial Markets bought a new position in Absci in the 4th quarter valued at $28,000. Finally, Verdence Capital Advisors LLC bought a new position in Absci in the 4th quarter valued at $37,000. Institutional investors own 52.05% of the company’s stock.

Absci Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.